Clinical Trials Logo
  1. Home
  2. Portal Vein Thrombosis
  3. NCT02627053

Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study

Portal Vein Thrombosis Clinical Trial

Official title:
Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study

Clinical Trial Summary

Anticoagulant therapy is generally recommended for all patients presenting with acute symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin (LMWH) or unfractionated heparin and continuing with the vitamin K antagonists in most patients. Rivaroxaban is approved for the treatment of deep vein thrombosis and pulmonary embolism, but no studies have assessed the safety of rivaroxaban in the setting of splanchnic vein thrombosis. The investigators aim to collect prospective information on the safety of rivaroxaban in a pilot cohort of 100 patients with acute splanchnic vein thrombosis without liver cirrhosis.

Clinical Trial Description

Patients with splanchnic vein thrombosis are at increased risk of recurrent VTE and bleeding. Routine anticoagulation with unfractionated heparin or low molecular weight heparin followed by warfarin is recommended in this setting, but limited data is available to support this recommendation and more than 20% of these patients do not receive antithrombotic treatment due the fear for bleeding complications. The pharmacokinetic and pharmacodynamic characteristics of rivaroxaban make this drug an ideal alternative therapeutic strategy for the treatment of patients with SVT. Thanks to the oral route of administration, the short half-life, the high bioavailability, the predictable dose-response and the lack of effects on platelet activity, rivaroxaban could result as an important alternative to both LMWH and warfarin in the acute and long-term treatment of SVT patients. Furthermore, the analysis of phase III studies conducted in patients with DVT or PE have shown a better safety profile of rivaroxaban as compared to standard of treatment. This observed benefit in the safety profile of rivaroxaban would be extremely relevant in the treatment of patients with SVT. In this prospective cohort study, patients presenting with acute SVT will receive rivaroxaban 15 mg bid for 3 weeks followed by rivaroxaban 20 mg od for a total of 3 months. The primary safety and efficacy outcomes will be measured at 3 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02627053
Study type Interventional
Source Università degli Studi dell'Insubria
Contact GIOVANNA COLOMBO
Email givacolo@hotmail.it
Status Recruiting
Phase Phase 3
Start date December 2015
Completion date December 2019
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03631147 - The Effect of Rifaximin on Portal Vein Thrombosis N/A
Completed NCT02250391 - Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis Phase 3
Recruiting NCT05625893 - Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion Phase 2
Completed NCT05012501 - Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients
Terminated NCT00769873 - Anticoagulation Post Laparoscopic Splenectomy Phase 2
Recruiting NCT05123326 - Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
Completed NCT01095185 - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding Phase 3
Completed NCT02585713 - Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Phase 3
Not yet recruiting NCT06117488 - Risk Factors and Management Outcome of Chronic Portal Vein Thrombosis in Children
Completed NCT01326949 - Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis N/A
Not yet recruiting NCT05339581 - IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation N/A
Recruiting NCT03902678 - Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma N/A
Not yet recruiting NCT06319131 - Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT N/A
Recruiting NCT03193502 - Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis Phase 3
Completed NCT03201367 - Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV N/A
Completed NCT03477149 - EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications N/A
Recruiting NCT02398357 - The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Phase 4
Completed NCT01556282 - TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis N/A
Withdrawn NCT01631877 - Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver N/A
Recruiting NCT04433481 - Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis N/A